

## Personal Information



## Unchalee Permsuwan

**Address:** Faculty of Pharmacy, Chiang Mai University  
**Country:** Thailand

## Curriculum Vitae

### Degree

- Bachelor of Pharmacy 1991 Chiang Mai University, Thailand
- Master of Science (Clinical Pharmacy) 1993 Mahidol University, Thailand
- Master of Science (Pharmacy) 1998 University of North Carolina at Chapel Hill, USA
- Doctor of Philosophy (Pharmacy) 2001 University of South Carolina, USA

### Research Experiences

### Publication

1. **Permsuwan U**, Thavorn K, Dilokthornsakul P, Saokaew S, Chaiyakunapruk N. Cost effectiveness of insulin detemir versus insulin glargine for Thai type 2 diabetes from a payer's perspective. *Journal of Medical Economics* 2017. Jul 11:1-9.
2. Yoodee J, **Permsuwan U**, Nimworapan M. Efficacy and safety of olanzapine for the prevention of chemotherapy - induced nausea and vomiting: A systematic review and meta-analysis. *Critical Review of Oncology and Hematology* 2017. Apr;112:113 - 125.
3. Thongprasert S, **Permsuwan U**. Crizotinib treatment for advanced non -small cell lung cancer patients: a budget impact analysis based in Thailand. *Current Medical Research and Opinion* 2017. May;33(5):955-61.
4. **Permsuwan U**, Dilokthornsakul P, Thavorn K, Saokaew S, Chaiyakunapruk N. Cost-effectiveness of dipeptidyl peptidase-4 inhibitor monotherapy versus sulfonylurea monotherapy for people with type 2 diabetes and chronic kidney disease in Thailand. *Journal of Medical Economics* 2017 Feb 20(2):171-81 .
5. **Permsuwan U** , Dilokthornsakul P, Saokaew S, Thavorn K, Chaiyakunapruk N. Cost-effectiveness of dipeptidyl peptidase -4 inhibitor monotherapy in elderly type 2 diabetes patients in Thailand. *ClinicoEconomics and Outcomes Research* 2016 .8: 521 -529 .
6. **Permsuwan U** , Chaiyakunapruk N, Dilokthornsakul P, Thavorn K, Sa okaew S. Long -term cost -effectiveness of insulin glargine versus neutral protamine hagedorn insulin for type 2 diabetes in Thailand. *Applied Health Economics and Health Policy* 2016. 14(3): 281 -92.
7. Thongprasert S, Crawford B, Sakulbumrungsil R, Chaiyakunapruk N, Petcharapiruch S, Leartsakulpanitch J, **Permsuwan U** . Willingness to pay for lung cancer treatment: patient versus general public values. *International Journal of Technology Assessment in Health Care* 2015 ; 31:4:1-7 .
8. **Permsuwan U**, Chaiyakunapruk N, Nathi suwan S, Sukonthasarn A. Cost -effectiveness

- analysis of fondaparinux vs enoxaparin in non-ST elevation acute coronary syndrome in Thailand. *Heart, Lung and Circulation* 2015; doi:10.1016/j.hlc.2015.02.018
9. Chong HY , Saokaew S, Dumrongpratt K, **Permsuwan U** , Wu DBC, Sritara P, Chaiyakunapruk N. Cost -effectiveness analysis of pharmacogenetic- guided warfarin dosing in Thailand. *Thrombosis Research* 2014; 134: 1278 - 84.
  10. Suwankesawong W, Saokaew S, **Permsuwan U**, Chaiyakunapruk N. Characterization of hypersensitivity reactions reported among *Andrographis paniculata* users in Thailand using Health Product Vigilance Center (HPVC) database. *BMC Complementary and Alternative Medicine* 2014; 14:515.
  11. Yamwong S, **Permsuwan U**, Tinmanee S, Sritara P. Long -term cost effectiveness of ticagrelor in patients with acute coronary syndromes in Thailand. *Health Economics Review* 2014; 4:17.
  12. **Permsuwan U** , Guntawongwan K, Buddhawongsa P. Handling time in economic evaluation studies. *Journal of Medical Association of Thailand* 2014; 97(Suppl5): S50 - 8.
  13. Buasi N, **Permsuwan U**. Validation of the Thai QOL- AD version in Alzheimer's patients and caregivers. *Australasian Medical Journal* 2014; 7: 251 -9
  14. **Permsuwan U**, Niamhun N, Tanatip N, Thongrasert S. First-line gefitinib treatment with epidermal growth factor receptor mutation testing in Thailand: A cost -utility analysis. *Value in Health Regional Issues* 2014; 3:39- 43.
  15. Thongprasert S, **Permsuwan U**. Resource constraints as a barrier to lung cancer management: developing nations. *Health* 2014; 6:845- 51.
  16. Saokaew S, **Permsuwan U**, Chaiyakunapruk N, Nathisuwan S, Sukonthasarn A, Jeanpeerapong N. Cost-effectiveness of pharmacist-participated warfarin therapy management in Thailand. *Thrombosis Research* 2013;132:437 -43.
  17. **Permsuwan U**, Pimkrai A, Niwatananun W. Cost -utility of donepezil for the treatment of Alzheimer's disease. *Journal of Mental Health of Thailand* 2013;21:138- 49.
  18. Chantrapunth W, Songkamchum S, Supajatura V, **Permsuwan U**. Comparative study on costs of vaccination between pre -exposure and post exposure rabies among high risk group. *Disease Control Journal* 2013; 39: 110-8.